Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 16/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 7/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.42 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.42 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.42 |
| ▸ | ATM | Q13315 | 11/20 | 0.40 |
| ▸ | ATR | Q13535 | 4/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3513886 | 0.99 | MTOR (0.45) | MTORPIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL3516018 | 0.95 | ATM (0.44) | MTORPIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL3516504 | 0.95 | MTOR (0.43) | MTORPIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL3514804 | 0.92 | MTOR (0.43) | MTORPIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL3515241 | 0.88 | MTOR (0.41) | MTORPIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL3515474 | 0.87 | MTOR (0.40) | MTORPIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL3515369 | 0.87 | ATM (0.48) | MTORPIK3CAATMATR | |
| SCHEMBL3515169 | 0.85 | MTOR (0.40) | MTORPIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL3514937 | 0.85 | MTOR (0.48) | MTORPIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL3515419 | 0.84 | ATM (0.49) | MTORPIK3CAPIK3CDPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140005163-A1 | 1H-IMIDAZO[4,5-C]QUINOLINONE DERIVATIVES | NOVARTIS AG (CH) | 2014-01-02 | — | — | US | claimed |
| US-20100317657-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES | NOVARTIS AG | 2010-12-16 | — | — | US | claimed |
| US-20140005163-A1 | 1H-IMIDAZO[4,5-C]QUINOLINONE DERIVATIVES | NOVARTIS AG (CH) | 2014-01-02 | — | — | US | disclosed |
| US-8476294-B2 | 1H-imidazo[4,5-c]quinolinone derivatives | NOVARTIS AG (CH) | 2013-07-02 | — | — | US | disclosed |
| US-8476294-B2 | 1H-imidazo[4,5-c]quinolinone derivatives | NOVARTIS AG (CH) | 2013-07-02 | — | — | US | disclosed |
| US-20100317657-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES | NOVARTIS AG | 2010-12-16 | — | — | US | disclosed |
| US-20100317657-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES | NOVARTIS AG | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317657-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES | PRKCA, CSNK1A1, ABL1 | MTOR 374/4885PIK3CA 125/4885PIK3CD 83/4885 |
| US-20140005163-A1 | 1H-IMIDAZO[4,5-C]QUINOLINONE DERIVATIVES | PRKCA, CSNK1A1, ABL1 | MTOR 374/4885PIK3CA 125/4885PIK3CD 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.